MediWound Ltd. (NASDAQ:MDWD) was up 16% during trading on Wednesday . The stock traded as high as $7.50 and last traded at $7.39, with a volume of 122,275 shares traded. The stock had previously closed at $6.37.

Several equities research analysts have recently commented on MDWD shares. Brean Capital reissued a “buy” rating on shares of MediWound in a research report on Saturday, April 23rd. Zacks Investment Research raised shares of MediWound from a “hold” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research report on Wednesday, April 27th. Jefferies Group decreased their target price on shares of MediWound from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, July 29th. Finally, Wells Fargo & Co. started coverage on shares of MediWound in a research report on Wednesday. They set an “outperform” rating for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $13.55.

The firm has a 50-day moving average of $7.47 and a 200-day moving average of $7.67. The stock’s market cap is $168.25 million.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.11. The firm had revenue of $3.36 million for the quarter, compared to analysts’ expectations of $0.45 million. The company’s revenue for the quarter was up 115.8% on a year-over-year basis. During the same period last year, the company posted ($0.19) earnings per share. On average, equities analysts predict that MediWound Ltd. will post ($1.04) EPS for the current year.

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.